Okubo Yoichiro, Yokose Tomoyuki, Motohashi Osamu, Miyagi Yohei, Yoshioka Emi, Suzuki Masaki, Washimi Kota, Kawachi Kae, Nito Madoka, Nemoto Tetsuo, Shibuya Kazutoshi, Kameda Yoichi
Department of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan.
Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, Kanagawa 241-8515, Japan.
Gastroenterol Res Pract. 2016;2016:5257312. doi: 10.1155/2016/5257312. Epub 2016 Dec 21.
Gangliocytic paraganglioma (GP) has been regarded as a rare benign tumor that commonly arises from the second part of the duodenum. As GP does not exhibit either prominent mitotic activity or Ki-67 immunoreactivity, it is often misdiagnosed as neuroendocrine tumor (NET) G1. However, the prognosis might be better in patients with GP than in those with NET G1. Therefore, it is important to differentiate GP from NET G1. Moreover, our previous study indicated that GP accounts for a substantial, constant percentage of duodenal NETs. In the present article, we describe up-to-date data on the clinicopathological characteristics of GP and on the immunohistochemical findings that can help differentiate GP from NET G1, as largely revealed in our new and larger literature survey and recent multi-institutional retrospective study. Furthermore, we would like to refer to differential diagnosis and clinical management of this tumor and provide intriguing information about the risk factors for lymph node metastasis on GP.
神经节细胞性副神经节瘤(GP)一直被视为一种罕见的良性肿瘤,通常起源于十二指肠第二部。由于GP既不表现出明显的有丝分裂活性,也不表现出Ki-67免疫反应性,因此常被误诊为神经内分泌肿瘤(NET)G1。然而,GP患者的预后可能比NET G1患者更好。因此,将GP与NET G1区分开来很重要。此外,我们之前的研究表明,GP在十二指肠NET中占相当大且恒定的比例。在本文中,我们描述了关于GP临床病理特征以及有助于将GP与NET G1区分开来的免疫组化结果的最新数据,这些数据主要来自我们新的、更大规模的文献调查以及近期的多机构回顾性研究。此外,我们还将提及该肿瘤的鉴别诊断和临床管理,并提供有关GP淋巴结转移风险因素的有趣信息。